Immunotherapy is all the rage these days in oncology  and there is particular interest in those agents that target programmed death 1 (PD-1) and its ligand  PD-L1 In several solid tumors (and hematologic tumors as we saw at ASH last week) there is a race to market for this class of compounds by multiple competitors